We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
-8.6%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$901M
AUM Growth
-$215M
Cap. Flow
-$75.2M
Cap. Flow %
-8.35%
Top 10 Hldgs %
51.77%
Holding
78
New
10
Increased
19
Reduced
15
Closed
15

Top Buys

1
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
+$17.3M
2
HRTX icon
Heron Therapeutics
HRTX
+$16.5M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$13.9M
4
VCYT icon
Veracyte
VCYT
+$13.4M
5
ZBH icon
Zimmer Biomet
ZBH
+$9.22M

Top Sells

1
NVDQ
Novadaq Technologies Inc.
NVDQ
+$43.2M
2
ANGO icon
AngioDynamics
ANGO
+$23.7M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$18.9M
4
DVAX
Dynavax Technologies
DVAX
+$14.1M
5
AEGR
Aegerion Pharmaceuticals
AEGR
+$13M

Sector Composition

1 Healthcare 88.9%
2 Financials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADXS
26
DELISTED
Advaxis Inc
ADXS
$10.9M 1.21%
101,284
-3,028
-3% -$409K
BDSI
27
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$9.45M 1.05%
5,398,794
+210,000
+4% +$429K
ZGNX
28
DELISTED
Zogenix, Inc.
ZGNX
$9.31M 1.03%
766,412
-115,900
-13% -$1.27M
BCR
29
DELISTED
CR Bard Inc.
BCR
$9.03M 1%
+40,200
New +$8.74M
AMRN
30
Amarin Corp
AMRN
$292M
$8.73M 0.97%
141,682
-26,270
-16% -$1.67M
SPNE
31
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$8.69M 0.96%
1,100,007
– –
ZBH icon
32
Zimmer Biomet
ZBH
$17.6B
$8.62M 0.96%
+86,005
New +$9.22M
CPRX icon
33
Catalyst Pharmaceutical
CPRX
$8.61M 0.96%
8,200,000
– –
ELGX
34
DELISTED
Endologix Inc
ELGX
$8.58M 0.95%
150,000
+70,000
+88% +$6.41M
CORI
35
DELISTED
Corium International, Inc.
CORI
$7.79M 0.87%
1,919,721
– –
SBBP
36
DELISTED
Strongbridge Biopharma plc.
SBBP
$6.95M 0.77%
2,894,581
+1,237,875
+75% +$5.05M
ACGN
37
DELISTED
Aceragen Inc
ACGN
$6.64M 0.74%
32,590
+14,721
+82% +$3.51M
CDTX
38
DELISTED
Cidara Therapeutics
CDTX
$5.85M 0.65%
28,144
+19,800
+237% +$4.11M
ADMA icon
39
ADMA Biologics
ADMA
$2.02B
$5.7M 0.63%
1,113,293
– –
MDT icon
40
Medtronic
MDT
$106B
$5.34M 0.59%
+75,000
New +$5.89M
PCRX icon
41
Pacira BioSciences
PCRX
$1.01B
$4.87M 0.54%
150,680
– –
GKOS icon
42
Glaukos
GKOS
$9.21B
$4.85M 0.54%
+141,300
New +$4.84M
PCRX icon
43
CALL
Pacira BioSciences
PCRX
$1.01B
$4.84M 0.54%
150,000
– –
SCYX icon
44
SCYNEXIS
SCYX
$42.4M
$4.71M 0.52%
18,466
– –
ARCT icon
45
Arcturus Therapeutics
ARCT
$172M
$4.32M 0.48%
293,872
+1,379
+0.5% +$20.6K
VXRT
46
DELISTED
Vaxart
VXRT
$4.29M 0.48%
316,974
– –
EGLT
47
DELISTED
Egalet Corporation
EGLT
$4.25M 0.47%
556,233
-578,517
-51% -$4.24M
NVET
48
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
$4.21M 0.47%
1,127,200
+109,945
+11% +$454K
MRTX
49
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.92M 0.44%
826,001
-173,999
-17% -$947K
TENX icon
50
Tenax Therapeutics
TENX
$420M
$3.84M 0.43%
62
– –
1
2
3 4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q4 2016 Portfolio in Review

As of Q4 2016, Broadfin Capital held 78 positions worth $901M, down 19% from $1.12B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Broadfin Capital withdrew a net $75.2M in Q4 2016, closing 15 positions and reducing 15 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $18.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 85% a quarter earlier, followed by Financials.

Against the trend, Broadfin Capital opened a new position in Novelion Therapeutics Inc. Common Shares worth $16.4M.

  • Broadfin Capital's largest Q4 2016 buy was Novelion Therapeutics Inc. Common Shares: 1,948,554 shares worth $16.4M.
  • Broadfin Capital added most to Heron Therapeutics in Q4 2016, an estimated $16.5M increase.
  • Broadfin Capital's biggest Q4 2016 reduction was Novadaq Technologies Inc., cutting an estimated $43.2M.
  • Broadfin Capital fully exited IVERIC bio, Inc. Common Stock in Q4 2016, selling an estimated $18.9M.
  • Broadfin Capital's ten largest holdings make up 52% of its $901M portfolio in Q4 2016.
  • Broadfin Capital opened 10 new positions and closed 15 in Q4 2016.
  • Broadfin Capital's portfolio value fell 19% quarter-over-quarter to $901M.

Based on Broadfin Capital's 13F filing for Q4 2016, filed 14 Feb 2017.